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Abstract
Parkinson disease is mainly characterized by the degeneration of dopaminergic neurons in the central nervous
system, including the retina. Different interrelated molecular mechanisms underlying Parkinson disease-associated
neuronal death have been put forward in the brain, including oxidative stress and mitochondrial dysfunction.
Systemic injection of the proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to monkeys elicits the
appearance of a parkinsonian syndrome, including morphological and functional impairments in the retina. However,
the intracellular events leading to derangement of dopaminergic and other retinal neurons in MPTP-treated animal
models have not been so far investigated. Here we have used a comparative proteomics approach to identify
proteins differentially expressed in the retina of MPTP-treated monkeys. Proteins were solubilized from the neural
retinas of control and MPTP-treated animals, labelled separately with two different cyanine fluorophores and run
pairwise on 2D DIGE gels. Out of >700 protein spots resolved and quantified, 36 were found to exhibit statistically
significant differences in their expression levels, of at least ±1.4-fold, in the parkinsonian monkey retina compared
with controls. Most of these spots were excised from preparative 2D gels, trypsinized and subjected to MALDI-TOF
MS and LC-MS/MS analyses. Data obtained were used for protein sequence database interrogation, and 15 different
proteins were successfully identified, of which 13 were underexpressed and 2 overexpressed. These proteins were
involved in key cellular functional pathways such as glycolysis and mitochondrial electron transport, neuronal
protection against stress and survival, and phototransduction processes. These functional categories underscore that
alterations in energy metabolism, neuroprotective mechanisms and signal transduction are involved in MPTP-
induced neuronal degeneration in the retina, in similarity to mechanisms thought to underlie neuronal death in the
Parkinson’s diseased brain and neurodegenerative diseases of the retina proper.
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Introduction
Parkinson disease (PD) is one of the most common
progressive neurodegenerative disorders in our society,
affecting over 1% of the aged people in Western countries and
with a current estimated prevalence in the world of around 4.5
million persons [1]. Collected under the term parkinsonism, the
symptoms exhibited by patients with this disease include
resting tremor, rigidity, postural instability and bradykinesia [2].
The causal origin of PD is unknown in most cases, and
treatments available today, based on the administration of
levodopa and dopamine analogues, although substantially
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ameliorate clinical symptoms, do not alter the course of
disease [3]. This is characterized by the massive, progressive
and irreversible degeneration of dopaminergic cell bodies
located in the midbrain substantia nigra and their axon
terminals in the striatum, and by their cytoplasmic accumulation
of typical protein fibrillar inclusions, named Lewy bodies [2,4].
This leads to a decrease in the substantia nigra of the levels of
Tyr hydrolase (TH), the characteristic enzyme of dopaminergic
neurons, and a decrease of the neurotransmitter dopamine in
the striatum. Although the etiology of parkinsonism is still
largely unknown, it is nowadays considered as a multifactorial
disease beyond any doubt. Hence, although considerable
progress has been made on the identification of genes
associated with the development of parkinsonism, the action of
environmental factors, mostly unknown, is recognized to be the
cause of most cases of common (sporadic or idiopathic) PD
[1,5,6]. In this context, some neurotoxins are known to induce
the selective destruction of dopaminergic neurons, such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-
hydroxydopamine and a variety of metals and pesticides, such
as rotenone, whose administration to monkeys and rodents has
allowed the generation of animal models of idiopathic PD [7–9]
that add up to available rodent genetic models [10]. Extensive
research on these experimental systems together with
available PD patients has led to envision a series of molecular
mechanisms as accounting for the pathophysiology of PD,
including oxidative stress, mitochondrial dysfunction and
excitotoxic damage [5,6,11,12], among others including
mutations in genes encoding proteins with a neuroprotective
role, such as parkin [2,5]. In this context lies the repeated
finding in PD patients of decreased activity of complex I of the
electron transport chain and, recently, of mitochondrial DNA
deletions [13]. Hence, the chemical inhibition of complex I by
systemically-administered MPTP, 6-hydroxydopamine or
rotenone recapitulates dopaminergic neuron degeneration and
associated neurological disability in experimental animals [6,7].
Also, the proposed prooxidant intracellular status generated by
a cytoplasmic accumulation of dopamine, resulting from its
defective vesicular storage, has been postulated to lead
dopaminergic neurons to apoptosis [11,14].
The mammalian retina is the tissue with the most active
metabolism in the organism and hence exhibiting the highest
O2 consumption. Any impairment in mitochondrial activity,
induced for instance by the above neurotoxic agents, is thus
expected to greatly affect the retina as part of the central
nervous system (CNS). A growing body of experimental
evidence has accumulated concerning visual dysfunction in the
retina of parkinsonian patients including loss of visual acuity,
contrast sensitivity, colour discrimination and motion perception
[15–17]. The relevance of macaques treated with MPTP [18,19]
or 6-hydroxydopamine [20] as a model of parkinsonism in the
retina was initially supported by a series of studies highlighting
a number of dysfunctional features detectable by
electroretinogram and visual evoked potential recordings,
which are similar to those reported in PD patients. These
deficits have been correlated by our group with a series of
morphological alterations occurring in the retina of MPTP-
treated monkeys, where loss of TH immunoreactivity in the
substantia nigra was accompanied by the degeneration of both
retinal dopaminergic neurons and their postsynaptic AII
amacrine cells, together with synapses formed among these
neuronal subtypes in the inner plexiform layer [21]. More
recently, we have also characterized the cellular and functional
impairments taking place in the retina of rotenone-treated rats,
where damage extended not only to dopaminergic neurons, but
also to photoreceptors and their synaptic connectivity [22].
Deficiencies occurring at the molecular level in the
parkinsonian retina are, however, essentially unknown, as are
the particular mechanisms by which MPTP or rotenone elicits
the degeneration of dopaminergic cells and other retinal
neurons. In this work we have investigated the alterations in
the retinal proteome taking place in the MPTP-treated monkey
model of PD, in order to provide insight into the molecular
mechanisms underlying neuronal degeneration in the retina
under parkinsonism. Most of the proteins identified as
differentially expressed in parkinsonian monkeys were found to
be downregulated, and their functions were related to cellular
energy metabolism, neuroprotection against stress and visual
signal transduction.
Materials and Methods
Biological Material and Ethics Information
All studies were carried out in accordance with the guidelines
promulgated by the European Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientific
Purposes of the Council of Europe (no. 123; June 15th, 2006),
and following the Code of Ethics of the European Directive
2010/63/EU and the U.S. National Institutes of Health (NIH). All
protocols and animal handling procedures used were approved
by the bioethics research committee of the Universidad de
Murcia [23]. Long-tailed macaques (Macaca fascicularis) were
imported from R.C. Hartelust B.V. (Tilburg, the Netherlands)
and housed at the animal care facility of the Universidad de
Murcia under supervision by veterinarians and technicians
skilled in the health care and maintenance of non-human
primates. The animals were maintained in cages of 65 x 75 x
95 cm in a primate house under temperature (25°C) and
humidity (50%) controlled conditions and a 12 h light/12 h dark
cycle (lights on at 8:30 AM), and they had free access to
special food (Masuri primate diet; Scientific Dietary Services,
UK), fresh fruit and water. Even though animals were housed in
partners, the arrangement of cages allowed each individual to
have visual contacts and interaction with monkeys housed in
adjacent cages. Animals used in the present work had not
been utilized for any prior research.
Experiments were performed on three adult macaques (4-6
kg; both sexes) that were rendered parkinsonian upon
treatment with MPTP hydrochloride (Sigma; 0.3 mg/kg i.v. for
several months, 1 injection every 2 weeks). Monkeys were
injected in the saphenous vein under gentle restraint and were
never given levodopa or dopaminergic agonists. The number of
MPTP doses administered was adjusted according to each
animal’s susceptibility to this compound, until a stable
parkinsonian syndrome was reached [21,23]. Three additional,
age-matched monkeys were kept without injections under the
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same conditions as the three treated, and used as control
subjects. The total dose of MPTP and the time necessary to
obtain sustained parkinsonian features ranged from 20 to 24
mg and from 26 to 28 weeks, respectively. This protocol
represents a reproducible MPTP cumulative dosing regimen
that leads to the first appearance of parkinsonian clinical signs
after 6 ± 1 injections. Animal behaviour was assessed both in
their home cages and in special observation cages for filming.
One special cage, measuring 1 m3, was designed so that an
independent camera located in front of the cage, in a special
space separated from the animals with methacrylate, could
perform independent recordings from each animal. The
parkinsonian syndrome was independently analyzed by several
scientists accustomed to evaluating motor disabilities in
monkeys, which was carried out by coaxing the animals to
perform various tasks upon offering them appetizing fruits. The
degree of parkinsonism was scored twice weekly, over a 10
min observation period with respect to control animals, on the
basis of a validated parkinsonian macaque clinical motor scale
ranging from 0-2 (normal) to 25 (maximum severity) [24]. This
scale covers eight features of motor disability induced by
MPTP: spontaneous activity (0-5), bradykinesia (0-3), tremor
duration (0-3), tremor intensity (0-3), posture (0-3), balance
(0-2), freezing (0-3) and feeding (0-3).
No animal was sacrificed solely for the purpose of the
research reported here, but instead other body parts were
harvested by different researchers for a range of unrelated
experiments, and their suffering was minimized at all times
during this procedure [23]. The monkeys were anesthetized
with ketamine (10 mg/kg i.m.) and then administered a lethal
injection of pentobarbital (50 mg/kg i.p.). Eyeballs were then
enucleated, and the neural retina was dissected free from the
retinal pigment epithelium, frozen in liquid N2 for transport to
the Universidad de Alicante and stored at -80°C until use.
Protein Extraction and Processing
Retinal tissue samples were thawed at room temperature
and homogenized in lysis buffer (20 mM Hepes pH 7.9, 10%
glycerol, 10 mM KCl, 0.4 M NaCl, 0.1% Nonidet P-40 and 2
mM DTT) supplemented with protease inhibitors (1 mM PMSF,
10 μM leupeptin, 0.3 μM aprotinin, 100 μM benzamidine). After
incubation on ice for 15-20 min with occasional gentle shaking,
samples were centrifuged at 13,000 rpm for 10 min at 4 °C.
The supernatant, containing solubilized proteins, was aliquoted
and stored at -80°C. Protein concentration was quantified
spectrophotometrically at 595 nm using the Bradford reagent
(Sigma) and BSA as a standard.
Solubilized proteins (200 μg for analytical gels, 900 μg for
preparative gels) were preincubated in 0.2 mg/l sodium
deoxycholate (Sigma) for 15 min on ice. Then, they were
precipitated by addition of trichloroacetic acid to 6% and
incubation for 30 min on ice, and recovered by centrifugation at
16,000×g for 15 min at 4 °C. The pellet obtained was washed
twice with 1.5 ml of 80% acetone (precooled at -20°C),
centrifuging each time at 16,000×g for 15 min at 4 °C. Then the
pellet was dried for 15 min at room temperature, and dissolved
by vigorous stirring in 100 μl of 2D lysis buffer composed of 7
M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS) and 30 mM
Tris base. The proteins were purified with the 2-D Clean-Up kit
from GE Healthcare (Buckinghamshire, UK) and finally
dissolved in 40 μl of 2D lysis buffer by vigorous shaking and
sonication for 10 min. Protein concentration was quantified
using the RC-dC Protein Assay from Bio-Rad (Hercules, CA).
Fluorescent Labelling of Proteins
The pH of samples (50 μg of protein) for DIGE was adjusted
to 8.5-9.0 by adding 1-2 μl of 100 mM NaOH. Then cyanine
fluorescent dyes (GE Healthcare) were conjugated to
solubilized proteins via N-hydroxysuccinimidyl linkages
following the manufacturer’s minimal labelling protocol. Briefly,
the parkinsonian or control protein sample was taken to a
volume of 18 μl with 2D lysis buffer and labelled alternately with
Cy3 (green) or Cy5 (red) by addition of 1 μl of 0.4 mM
fluorophore in N,N-dimethylformamide. Separately, an internal
standard was prepared consisting of a pool of identical
amounts of protein from the six monkey retinal samples
labelled with Cy2. Reactions were carried out for 30 min on ice
in the dark, and quenched by addition of 1 μl of 10 mM Lys and
further 10 min incubation. For each gel, 50 μg of control group
sample and 50 μg of MPTP group sample, each labelled with a
different dye, was mixed with 50 μg of Cy2-labelled internal
standard, to obtain a 65 μl mixture containing 150 μg of protein.
Then DIGE sample buffer containing 7 M urea, 2 M thiourea,
2% CHAPS, 2% IPG buffer pH 4-7 (GE Healthcare) and 130
mM DTT was added to a final volume of 130 μl, and the
mixture was incubated on ice for further 15 min. To avoid
biasing due to the dye, half of the samples of each
experimental group were labelled with Cy3 and the other half
with Cy5 [25].
2D Gel Electrophoresis
For IEF in the first dimension 18 cm-long Immobiline
DryStrips (GE Healthcare) were used, containing immobilized
ampholytes forming a linear pH 4-7 gradient. The strips were
rehydrated in 350 μl of a buffer containing 7 M urea, 2 M
thiourea, 2% CHAPS, 2% IPG buffer pH 4-7, 18 mM DTT and
traces of bromphenol blue, for 16 h at room temperature
covered with mineral oil. The samples were applied onto the
strips following a cup loading protocol, and IEF was performed
at room temperature in an Ettan IPGphor II unit (GE
Healthcare) at 50 mA per IPG strip, according to the following
program: fast gradient to 300 V for 3 h, linear gradient to 1,000
V for 6 h, linear gradient to 8,000 V for 3 h, and fast gradient to
8,000 V for 4 h, totalling 40,000 V·h at the end of the run.
After IEF, the IPG strips were incubated with shaking for 15
min in equilibration buffer I (6 M urea, 30% glycerol, 2% SDS,
50 mM Tris-HCl pH 8.8, 1% DTT), and then for further 15 min
in equilibration buffer II (buffer I in which DTT was replaced by
1.25% iodoacetamide). Thereafter, they were individually
applied onto the surface of a vertical 12.5% polyacrylamide gel
and sealed with 0.5% agarose dissolved in electrophoresis
buffer (25 mM Tris-HCl pH 8.3, 192 mM Gly, 0.1% SDS) with
traces of bromphenol blue. SDS-PAGE Broad Range or All
Blue Precision Plus Protein (Bio-Rad) molecular weight
standards were loaded by each end of the strip, and the
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second-dimension electrophoresis was carried out in a
DALTsix Ettan unit (GE Healthcare) at a constant current of 10
mA for 14-16 h, or 40 mA for 4-5 h.
Gel Scanning and Staining
Following electrophoresis, signals from the three
fluorophores in each gel were sequentially scanned on a
Typhoon 9410 fluorescence imager (GE Healthcare) at a
photomultiplier voltage of 500 V and a pixel size of 100 μm
(254 dpi resolution). For Cy3, excitation and emission
wavelengths used were 532 and 580 nm, respectively, and for
Cy5 633 and 670 nm. Cy2 images were obtained at
wavelengths of 488 and 520 nm.
DIGE gels were stained with silver nitrate, essentially as
previously described [26]. Preparative gels were stained with
colloidal Coomassie Blue according to established procedures
[27], with some modifications. Briefly, gels were fixed in 50%
ethanol and 2% phosphoric acid for 3 h and, after washing with
milliQ H2O, incubated for 1 h in staining solution (3%
phosphoric acid, 35% methanol, 100 mM ammonium sulfate).
Then Coomassie Brilliant Blue G-250 solution in methanol
(USB, Cleveland, OH) was added to a concentration of 0.65 g/l,
and the gels were incubated for 14-16 h at room temperature.
After destaining with milliQ H2O, they were stored in 5% acetic
acid at 4 °C. Gels were digitized on an UVIdoc Documentation
System (UVItec, Cambridge, UK).
MS Analyses and Database Search for Protein
Identification
With the aim of identifying the proteins detected in the retina
as differentially expressed in control vs. MPTP-treated
monkeys, the spots were manually excised from Coomassie
Blue-stained preparative polyacrylamide gels using a manual
spot picker (Gel Company, Tübingen, Germany) with a 1.5 mm
diameter picker head, and processed for trypsin digestion by
using an Investigator Progest protein workstation (Genomic
Solutions, Cambridgeshire, UK). The protein spots were
washed sequentially in this system with 25 mM ammonium
bicarbonate and then with H2O, and thereafter subjected to
reduction with 10 mM DTT and alkylation with 100 mM
iodoacetamide in 50 mM ammonium bicarbonate. The proteins
were then digested with modified porcine trypsin from Promega
(Madison, WI), in 25 mM ammonium bicarbonate for 6-7 h at
37 °C. The resulting peptides were sequentially extracted with
ammonium bicarbonate, then with 70% acetonitrile, and finally
with 1% formic acid.
For MALDI-TOF MS analysis, the peptides were dried under
vacuum in a SpeedVac system for at least 1 h at 60°C. Then
they were purified and concentrated on Zorbax 300SB-C18
silica gel tips (Agilent Technologies, Santa Clara, CA), and
redissolved in 5 μl of a 0.1% trifluoroacetic acid: acetonitrile
mixture (2:1). One μl of sample was spotted onto a MALDI
plate (MTP AnchorChip 400/384 TF, from Bruker Daltonics,
Bremen, Germany) together with 1 μl of 2,5-dihydroxybenzoic
acid matrix dissolved in the same trifluoroacetic acid:
acetonitrile mixture. Prior to analysis, the sample was allowed
to dry on the matrix and an external calibration of the MALDI-
TOF Autoflex mass spectrometer was performed using the
PeptideMix peptide standard (both from Bruker Daltonics). The
peptides in each sample were ionized with a 337-nm N2 laser,
and mass spectra were acquired in the positive ion mode at a
reflectron voltage of 20 kV by averaging 30 laser shots. The
range of masses considered was 800-3500 Da, suitable to
cover in general the majority of peptides from trypsin digestion.
For LC-MS/MS, tryptic peptides were SpeedVac-dried as
above and redissolved in 15 μl of 0.1% formic acid. LC-MS/MS
analysis was performed using an Agilent 1100 nano-high-
performance liquid chromatography system coupled to a mass
spectrometer equipped with an XCTplus ion trap and an
electrospray ionization source (Agilent Technologies). After
concentration and desalting of peptides by employing a Zorbax
300SB-C18 column (0.3 mm × 5 mm, 5 μm) at a flow rate of
0.3 μl/min, they were separated on a Zorbax 300SB-C18
analytical column (75 μm × 15 cm, 3.5 μm) using a linear
gradient of 5-45% acetonitrile in 0.1% formic acid at a constant
flow of 0.3 μl/min, for 50 min. For acquisition of mass and
mass/mass spectra, the parameters previously indicated [28]
were used, with some modifications. Briefly, the spectra were
obtained using the standard enhanced and UltraScan modes,
at 26,000 and 8,100 m/z per second respectively. Parameters
included a ionization potential of 1.8 kV and an ICC smart
target (number of ions in the trap before acquisition) of 500,000
or a maximum accumulation time of 150 ms. MS/MS spectra
analyses were performed using automated switching with a
preference for +2 charged ions, a threshold of 105 counts and
a 1.3 kV fragmentation amplitude.
Peptide mass fingerprints obtained from MALDI-TOF MS
analysis were used to interrogate the NCBInr polypeptide
database by employing the Mascot search engine [29].
Parameters were configured as follows: maximum trypsin
missed cleavages, 1; fixed modification, Cys
carbamidomethylation; variable modification, Met oxidation;
peptide mass tolerance, ±100 ppm; mass values,
monoisotopic, and peptide charge state, 1+. Molecular weight
search (Mowse) scores were calculated by comparison of
search results against estimated random match population,
and reported as -10 × log (P) where P is the absolute
probability [30]. Only those identifications that met the following
criteria were considered as valid: significant (>80) Mowse
score, ≥4 peptides identified and sequence coverage >25%.
The MS/MS spectra obtained from LC-MS/MS analysis were
used to search the Swiss-Prot polypeptide database with the
Spectrum Mill Proteomics Workbench software rev. A.03.03
(Agilent Technologies). Parameters were set as: maximum
missed cleavages, 2; fixed modification, Cys
carbamidomethylation; variable modifications, Met oxidation,
Asn deamidation and pyro-Glu formation; and fragment mass
tolerance, ±0.7 and ±0.6 Da for parental and fragment ions,
respectively. Only those identifications that met the following
criteria were considered as valid: scores given by the Spectrum
Mill software, >8 to each peptide and >20 to the protein, and
sequence determined for at least 2 different peptides. The
automatic validation of each protein and peptide was verified
manually to avoid false positives. The raw data (mzXML) and
peak lists (*. PKL) are available as a 1.4 Gb compressed file
upon request to the corresponding author.
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Western Blotting
Retinal proteins were extracted and subjected to
immunoblotting analysis as previously described [31,32].
Proteins (25 or 75 μg/lane) were resolved by SDS-PAGE on 5–
20% polyacrylamide-gradient gels and electrotransferred to
Hybond-P PVDF membranes (GE Healthcare). These were
probed at 4 °C overnight with mouse monoclonal antibodies to
S-arrestin (clone SCT-128; provided by W. Clay Smith) at a
1:1,000 dilution, calbindin D28k (clone CB-955; Sigma) at a
1:500 dilution, to NDP kinase α (clone KM1121; Kamiya
Biomedical Company, Seattle, WA) at a 1:300 dilution, or to β-
actin (clone AC-15; Sigma) at a 1:20,000 dilution. Thereafter,
they were incubated at room temperature for 1 h with
horseradish peroxidase-conjugated goat anti-mouse IgG
(Pierce, Rockford, IL) at a 1:10,000 dilution. Detection was
performed by ECL using the SuperSignal West Dura system
(Pierce).
Statistical and Quantitative Analyses
The spot staining pattern of DIGE gels was analyzed using
the Progenesis SameSpots software v. 3.0 (Nonlinear
Dynamics, Newcastle, UK). Equivalent spots across gels were
matched, and images from control and parkinsonian monkeys
were separately grouped. Spots outlined by the program were
also visually inspected and manually edited when appropriate.
The amount of protein present in each spot was
densitometrically measured and its volume was calculated by
integration of the optical density over the spot’s area. Then
normalized volumes (NV) were obtained by dividing it by the
total volume over the whole set of gel spots (yielded by the
internal standard, labelled with Cy2), and the NV values of
each spot were separately averaged for control and MPTP-
treated monkeys. The fold change in protein expression was
calculated as the ratio between the higher and the lower of
each pair of values, and a minus sign (-) was added when the
lower was that of the treated group. The processing of
numerical data was performed using Microsoft Excel, and
statistical analyses were carried out using the Prism v. 5
program from GraphPad Software (San Diego, CA).
Significance of differences between treatments was evaluated
using the non-parametric Student’s t-test with a confidence
interval of 95%. In DIGE experiments the differences were
additionally evaluated by analysis of variance (ANOVA), and
only spots yielding a P value lower than 0.05 in both tests were
considered for further analysis.
Autoradiography films from Western blots were digitized
using an ImageScanner in transparency mode at 300 dpi and
16 bits grey scale, and image acquisition was performed using
the LabScan v. 5.0 software (both from GE Healthcare).
Densitometric quantitation of protein bands was accomplished
using ImageJ 1.42q [33], and values obtained for each protein
were normalized to β-actin levels. For each quantified protein
we analyzed the results of at least two independent
experiments, each containing a minimum of three biological
replicates.
Results
Three eyes were used for this study each from a different
macaque that had been chronically treated with MPTP and who
had developed a stable and persistent parkinsonian syndrome,
from moderate to severe as judged from its motor alterations.
Two of them exhibited a severe parkinsonism (motor disability,
16/25) and the third moderate parkinsonian symptoms (motor
disability, 13/25). These monkeys displayed bradykinesia/
akinesia, rigidity, freezing phenomena, action tremor and
paradoxical kinesias, as well as abnormal vertical and
horizontal saccadic ocular movements. They also showed
postural disturbances (trunk and limb flexion) and balance
alterations with occasional falls. Three additional, age-matched
monkeys kept without injections under the same conditions as
the three treated were used as control subjects (motor
disability, 0-2/25). After sacrifice, their eyes were enucleated
and their neural retinas dissected. Monkeys treated in the
same fashion and exhibiting comparable motor scores
displayed a substantial reduction of TH immunoreactivity in
both the substantia nigra and the retina, resulting in the
degeneration of dopaminergic cell bodies and dendritic plexi in
both tissues [21].
Analysis of Differential Protein Expression
Differences in the abundance of particular proteins in the
retina of parkinsonian vs. control monkeys were screened by
means of 2D DIGE technology. A preliminary 2D gel was run in
the pH range 3-10, where most detected proteins were
observed to fall within the pI interval 4-7. Therefore, this pI
range was subsequently used for the first-dimension IEF. For
the second dimension regular SDS-PAGE was carried out at a
fixed, 12.5% polyacrylamide concentration. Thereafter, the 2D
gels were scanned with a Typhoon 9410 Variable Mode Imager
and the spot maps obtained were bioinformatically analyzed
using the Progenesis SameSpots software. A representative
DIGE gel is shown in Figure 1, where separate images
corresponding to the proteins from a control parkinsonian
monkey retina (labelled in green) and from an MPTP-treated
subject (labelled in red) are shown in Figure 1A and 1B,
respectively. The merged image is shown in Figure 1C, where
yellow spots represented proteins with similar expression levels
in both samples and were thus not considered.
Over 700 discrete spots were clearly resolved on 2D DIGE
gels. The electrophoretic pattern obtained was consistent for
retinal extracts from individuals of the same group (i.e. control
or MPTP-treated monkeys), although a certain variability was
observed attributable to the fact that the animals studied were
not isogenic. A bioinformatic analysis revealed that quantitative
differences existed for a total of 36 spots between the two
experimental groups, whose positions in 2D gels are
numerically labelled in Figure 1C. These spots were selected
for their variation exceeding an arbitrary threshold of 1.4-fold
increase (40%) or decrease (29%) in their expression levels
and for differences being concluded to be statistically
significant from both the Progenesis SameSpots software and
Student’s t-test. In particular, 34 spots exhibited a decrease of
expression above 1.4-fold in parkinsonian monkeys and 2
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Figure 1.  DIGE-resolved polypeptides from the retina of control and MPTP-treated monkeys.  A. Control monkey. B. MPTP-
treated monkey. C. Merged image resulting from superimposition of A (proteins labelled in green) and B (proteins in red). Yellow
spots correspond to polypeptides with similar expression levels in both samples. Differentially-expressed spots are circled, and the
indicated numbering was subsequently used throughout tables in this work.
doi: 10.1371/journal.pone.0074439.g001
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spots a higher than 1.4-fold increase with respect to controls
(Table 1). Among the 34 spots whose normalized volume had
diminished, the greatest decrease was observed for spot no. 2,
whose abundance was reduced by 2.97-fold (to 33.7%). On the
other hand, spots no. 5 and 37 had increased their normalized
volumes, by 2.52 and 1.41-fold respectively, in the retina of
MPTP-treated monkeys. Qualitative differences, i.e. spots that
were consistently absent in either of the two groups and
present in the other, were not detected.
Table 1. Polypeptides differentially expressed in the retina
of MPTP-treated versus control monkeys.
Spot no. Normalized volume Fold changea Pb
 Control MPTP   
1 0.994 ± 0.296 0.514 ± 0.094 -1.93 0.0261*
2 1.922 ± 0.936 0.648 ± 0.100 -2.97 0.0352*
3 1.370 ± 0.357 0.486 ± 0.174 -2.82 0.0043**
4 1.436 ± 0.333 0.534 ± 0.401 -2.69 0.0135*
5 0.635 ± 0.176 1.600 ± 0.606 2.52 0.0223*
7 1.382 ± 0.603 0.559 ± 0.197 -2.47 0.0410*
8 1.427 ± 0.588 0.585 ± 0.336 -2.44 0.0474*
11 1.668 ± 0.653 0.745 ± 0.222 -2.20 0.0366*
12 1.204 ± 0.289 0.746 ± 0.155 -1.61 0.0407*
13 1.361 ± 0.281 0.647 ± 0.226 -2.10 0.0074**
15 1.393 ± 0.181 0.673 ± 0.256 -2.07 0.0037**
17 1.438 ± 0.467 0.717 ± 0.165 -2.01 0.0269*
18 1.415 ± 0.472 0.710 ± 0.104 -1.99 0.0269*
20 1.185 ± 0.345 0.607 ± 0.287 -1.95 0.0421*
21 1.539 ± 0.479 0.792 ± 0.111 -1.94 0.0228*
24 1.376 ± 0.262 0.747 ± 0.087 -1.84 0.0039**
28 1.330 ± 0.323 0.733 ± 0.131 -1.81 0.0142*
31 1.385 ± 0.386 0.799 ± 0.097 -1.73 0.0257*
33 1.247 ± 0.363 0.746 ± 0.120 -1.67 0.0395*
34 1.540 ± 0.267 0.934 ± 0.221 -1.65 0.0128*
36 1.391 ± 0.316 0.845 ± 0.174 -1.65 0.0232*
37 0.949 ± 0.237 1.341 ± 0.104 1.41 0.0466*
38 1.554 ± 0.302 0.946 ± 0.376 -1.64 0.0453*
39 1.420 ± 0.345 0.871 ± 0.140 -1.63 0.0256*
41 1.374 ± 0.089 0.871 ± 0.277 -1.58 0.0135*
42 1.345 ± 0.273 0.861 ± 0.211 -1.56 0.0309*
43 1.265 ± 0.141 0.828 ± 0.162 -1.52 0.0066**
45 1.329 ± 0.131 0.931 ± 0.223 -1.43 0.0220*
46 1.388 ± 0.245 0.993 ± 0.124 -1.40 0.0279*
91 1.277 ± 0.358 0.816 ± 0.072 -1.56 0.0489*
115 1.463 ± 0.424 0.676 ± 0.353 -2.17 0.0430*
157 1.482 ± 0.528 0.864 ± 0.235 -1.71 0.0287*
204 1.204 ± 0.299 0.766 ± 0.278 -1.57 0.0192*
205 1.117 ± 0.221 0.711 ± 0.236 -1.57 0.0457*
237 1.197 ± 0.321 0.790 ± 0.204 -1.51 0.0382*
730 1.370 ± 0.409 0.743 ± 0.080 -1.84 0.0237*
a. Calculated by dividing the higher by the lower number in each pair of NV values,
and preceded by a minus (-) symbol when the lower was that of the MPTP-treated
sample.
Calculated for Student’s t-test (P <0.05, significant; P <0.01, highly significant).
Identification of Differentially-Expressed Proteins
From preparative 2D gels stained with colloidal Coomassie
Blue a series of proteins were recovered that exhibited altered
amounts in the parkinsonian monkey retina when compared to
controls. A total of 29 spots were selected on the basis of their
unequivocal visualization and localization in the preparative
gel, and following excision and trypsin digestion they were
subjected to MS analysis. Eighteen spots were successfully
identified by means of peptide mass fingerprinting and/or
MS/MS search analyses by interrogation of the NCBInr and
Swiss-Prot polypeptide databases, respectively, and the
characteristics of the corresponding proteins are summarized
in Table 2. In instances where these databases did not contain
any matching M. fascicularis protein sequence (most cases),
the identification was carried out on the basis of its homology to
the human (Homo sapiens), rhesus macaque (Macaca mulatta)
or chimpanzee (Pan troglodytes) ortholog sequence. Table 2
includes, in addition to protein names, their accession numbers
in the corresponding database (NCBInr and/or Swiss-Prot) and
the species to whom such sequence belongs. Also indicated
for each protein in Table 2 are its pI and Mr values, both
experimental (calculated from its migration position in 2D gels)
and theoretical (from its amino acid sequence in the database),
together with the MS method(s) allowing its identification.
Some spot pairs corresponded to the same protein, in
particular 3 and 115 (S-arrestin), 13 and 18 (DDAH1), and 20
and 237 (γ-enolase), which represented isoelectric variants
derived from proteolytic processing or other post-translational
modifications changing their intrinsic charge and/or mass. For
some of the identified proteins significant differences were
found between their experimental and theoretical pI (e.g. spots
1 and 37) or Mr (e.g. spots 13 and 20) values, which could be
attributed to the polypeptide excised from the gel harbouring
covalent modifications occurring post-translationally (e.g.
phosphorylation, glycosylation, etc.) or “accidentally” during
sample handling (e.g. oxidation), or else to its encoding mRNA
undergoing alternative splicing. For identifications carried out
by peptide mass fingerprinting followed by database screening
using the Mascot search engine, Table 2 shows each protein’s
Mowse score, taken as a confidence index, the number of
peptides whose mass was represented in the fingerprint, and
the sequence coverage. Mowse scores for this group of
proteins ranged between 133 and 294, the sequence coverage
between 53 and 73%, and the number of matching peptides
between 15 and 21. Table S1 gives for each protein spot the
number of peptide masses obtained by MALDI-TOF used for
database screening, the number of masses matching amino
acid segments of the identified protein, and sequences of the
latter. For identifications carried out by LC-MS/MS, the score
yielded by the Spectrum Mill software is given in Table 2,
together with the percentage of sequence coverage and the
number of identified peptides. For this group of proteins, which
constituted the vast majority, the MS/MS search scores varied
between 17.43 and 378.20, the sequence coverage between 6
and 58% and the number of peptides between 2 and 21. Those
with the lowest values for these three parameters, i.e. spots no.
20 and 34, were identified by de novo sequencing using the
Sherenga algorithm [34], illustrated in Figure S1. The
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sequences of the different peptides identified in each protein
spot by means of LC-MS/MS or de novo sequencing using
Sherenga are shown in Table S2. The corresponding score,
charge, scored peak intensities (SPI) and monoisotopic mass
of each identified peptide precursor are also indicated in Table
S2.
In total, a number of 15 different polypeptides were identified,
whose differential expression levels are illustrated in Figure 2.
These proteins are involved in a variety of functions within the
cell. Table 3 summarizes, for each protein, its encoding gene
and its accession number in the Gene Ontology (GO)
database, where data on biological processes, cellular
components and molecular functions associated with every
known protein are compiled [35]. These are as follows:
Spot no. 1, whose expression levels were decreased (by
1.93-fold) in the retina of MPTP-treated monkeys compared to
control animals (Table 1; Figure 2), was identified as α-
enolase, encoded by the ENO1 gene. This is a ubiquitous
protein in adult tissues which participates in a variety of
biological processes, such as growth control, hypoxia tolerance
and allergy, but whose main function is to act as a glycolytic
enzyme (Table 3) catalyzing the conversion of 2-phospho-D-
glycerate into phosphoenolpyruvate.
Spot no. 2 (which exhibited a 2.97-fold reduction of staining
intensity in the parkinsonian retina) was found to correspond to
Table 2. Identification by mass spectrometry of proteins differentially expressed in the retina of parkinsonian monkeys.
Spot no.Protein Accession no. a
pI exp. / pI
theor. b
Mr exp. / Mr
theor. b Analysis methodb
MALDI-TOFc
Score /
Sequence
coverage /
Number of
peptides
LC-MS/MSd
Score / Sequence
coverage /
Number of
peptides
1 α-Enolase P06733 (S, Hs), NP_001419(N, Hs) 4.75/6.99 48.2/47.1
LC-MS/MS, MALDI-
TOF 133/53/16 244.30/39/12
2 ATP synthase, subunit β P06576 (S, Hs) 4.75/5.00 52.4/51.8 LC-MS/MS  378.20/52/21
3 S-Arrestin P10523 (S, Hs) 6.25/6.14 51.5/45.1 LC-MS/MS  67.24/10/5
5 β-Crystallin B2 XP_001098886 (N, Mm) 6.14/6.54 27.7/23.2 MALDI-TOF 261/60/15  
7 Heat shock 70 kDa protein 8(HSC70) P11142 (N, Hs) 5.08/5.37 75.0/70.8 LC-MS/MS  65.84/8/4
12 Stathmin P16949 (N, Hs) 5.53/5.77 16.5/17.2 LC-MS/MS  31.58/15/2
13 N
G,NG-Dimethylarginine
dimethylaminohydrolase 1 (DDAH1) O94760 (S, Hs) 4.93/5.53 15.2/30.1 LC-MS/MS  152.41/34/8
18 DDAH1 O94760 (S, Hs), NP_036269(N, Hs) 5.32/5.53 36.9/30.1
LC-MS/MS, MALDI-
TOF 171/63/16 218.67/58/13
20 γ-Enolase P09104 (S, Hs) 5.44/4.91 32.2/47.1 LC-MS/MS  23.87/6e / 2e
21 Glucose-regulated 78 kDa protein(GRP78) P11021 (S, Hs) 4.67/5.01 82.1/72.3 LC-MS/MS  68.31/9/4
31 Glyceraldehyde 3-phosphatedehydrogenase (GAPDH) P04406 (S, Hs) 5.49/8.58 37.4/35.6 LC-MS/MS  53.30/10/3
33 Inorganic pyrophosphatase (PPA1) Q4R543 (S, Mf),XP_001164495 (N, Pt) 5.33/5.54 34.1/32.6
LC-MS/MS, MALDI-
TOF 231/65/18 135.79/35/8
34 Calbindin P05937 (S, Hs) 4.16/4.70 25.6/29.9 LC-MS/MS  17.43/8e/ 2e
37 Nucleoside diphosphate kinase B(NDPK B) P22392 (S, Hs) 5.30/8.52 16.8/17.3 LC-MS/MS  44.49/25/3
42 Cytochrome c oxidase (COX),subunit 5A Q53CF8 (S, Mm) 4.69/5.01 13.1/12.5 LC-MS/MS  36.40/16/2
91 γ-Synuclein Q2PFW6 (S, Mf) 4.50/4.98 15.4/13.3 LC-MS/MS  96.86/49/6
115 S-Arrestin P10523 (S, Hs) 6.06/6.14 50.6/45.1 LC-MS/MS  177.66/27/10
237 γ-Enolase P09104 (S, Hs), AAV67362(N, Mf) 4.54/4.91 48.5/47.1
LC-MS/MS, MALDI-
TOF 294/73/21 204.93/44/13
a. For each spot the protein identified is indicated together with its accession number in the interrogated polypeptide database (N, NCBInr; S, Swiss-Prot) and the
corresponding primate species (Hs, human; Mf, long-tailed macaque; Mm, rhesus macaque; Pt, chimpanzee).
b. The isoelectric point (pI) and relative molecular mass (Mr) are also given, both experimental and theoretical, together with the MS method(s) used for its identification.
c. The MOWSE score is indicated together with the fraction (%) of protein sequence covered by the identified peptides and the number of these represented in the mass
fingerprint.
d. The corresponding score is indicated together with the fraction (%) of sequence and the number of peptides identified.
e. Peptides identified by de novo sequencing using the Sherenga algorithm.
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Figure 2.  Levels of proteins differentially expressed in the retina of parkinsonian monkeys.  A–O. Each plot shows the
relative normalized volumes (RNV) for the identified polypeptides, obtained as the ratio between MPTP-treated (M) and control (C)
NV values, taking the latter as 100%. Bars represent the average ± SEM (n = 3). The statistical significance obtained by Student’s t-
test is indicated: * P <0.05; ** P <0.01. Representative spot pairs are also shown for each polypeptide, where the left spot
corresponds to a control monkey and the right to a parkinsonian individual.
doi: 10.1371/journal.pone.0074439.g002
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the β subunit of ATP synthase F1 component, encoded by the
ATP5B gene. This is a constituent protein of mitochondrial
complex V, i.e. the terminal complex in the electron transport
chain, whose well known function is to carry out ATP synthesis
from ADP by using the proton-motive force generated across
the mitochondrial inner membrane.
Adjacent spots numbered 3 and 115 (see Figure 1C) were
ascribed to presumable isoelectric variants of S-arrestin
(showing content decreases of 2.82- and 2.17-fold,
respectively). This is the product of the SAG gene, constituting
a major component of the outer segments of rod
photoreceptors where it participates in desensitization of the
phototransduction cascade [36]. This is exerted through S-
arrestin ability to bind and inhibit phosphorylated, light-
activated rhodopsin, thereby preventing activation of cGMP
phosphodiesterase mediated by transducin [36].
Spot no. 5 (whose normalized volume was increased by
2.52-fold in the parkinsonian retina) corresponded to β–
crystallin B2, the product of CRYBB2. Crystallins, the
majoritary structural components of the eye lens, are a
superfamily of oligomer-forming proteins whose function is to
increase the refractive index of the lens while maintaining its
transparency. Yet, an additional role of these proteins in retinal
neuron survival is becoming increasingly clear [37,38].
Spot no. 7 (displaying a 2.47-fold reduction in the MPTP-
treated retina) was identified as the heat shock 70 kDa protein
8 (HSC70), also called heat shock cognate 71 kDa protein.
This is the product of the HSPA8 gene, which codes for a
constitutively-expressed, cytosolic chaperone belonging to the
Hsp70 family responsible for the correct folding and assembly
of nascent polypeptides and degradation of misfolded proteins
by chaperone-mediated autophagy [37].
Spot 12 was ascribed to stathmin, the product of the STMN1
gene (presenting at lower levels, i.e. a 1.61-fold reduction, in
treated monkeys), which is involved in cytoskeleton dynamics
by preventing the assembly and promoting the disassembly of
microtubules in a phosphorylation-regulated manner [39].
Spots 13 and 18 (showing a decrease in their normalized
volumes by 2.10- and 1.99-fold, respectively) corresponded to
the product of the DDAH1 gene, NG, NG-dimethylarginine
dimethylaminohydrolase-1. This enzyme hydrolyzes both
asymmetric NG, NG-dimethyl-L-arginine (ADMA) and NG-
monomethyl-L-arginine (MMA), two competitive inhibitors of all
isoforms of nitric oxide synthase (NOS), to yield dimethylamine
and L-citrulline, which no longer inhibit NOS [40]. The DDAH1
enzyme thus represents a mechanism for modulation of NO
synthesis in both physiological and pathological states.
Spots 20 and 237 were also underexpressed in the retina of
parkinsonian macaques (by 1.95- and 1.51-fold respectively)
and were identified as pertaining to γ-enolase, a neuron-
specific protein encoded by ENO2. Like the α isoenzyme
above, γ-enolase participates in glycolysis by catalyzing the
conversion of 2-phospho-D-glycerate into
phosphoenolpyruvate. However, it also has neurotrophic and
neuroprotective properties on neurons, promoting their survival
in culture [41].
Spot 21 (whose intensity was found diminished 1.94-fold in
the treated monkey retina) corresponded to the 78 kDa
glucose-regulated protein (GRP78 or BiP), the product of the
HSPA5 gene. This is a chaperone mainly located at the
endoplasmic reticulum (ER) that, alike Hsc70, belongs to the
Hsp70 protein family. GRP78 not only is involved in correct
protein folding and the assembly of protein complexes in the
ER lumen, but also exhibits anti-apoptotic functions in neurons
[42].
Table 3. Function of differentially-expressed identified proteins.
Spot no. aProteinb Geneb GO accessionc Biological process / Functionc
1 α-Enolase ENO1 0006096; 0030308 Glycolysis; Negative regulation of cell growth
2 ATP synthase subunit β ATP5B 0022904; 0005753 Respiratory electron transport chain; Mitochondrial H+-transporting ATP synthase complex
3, 115 S-Arrestin SAG 0009586; 0007601 Rhodopsin mediated phototransduction; Visual perception
5 β-Crystallin B2 CRYBB2 0005212; 0007601 Structural constituent of eye lens; Visual perception
7 HSC70 HSPA8 0061077; 0006950 Chaperone-mediated protein folding; Response to stress
12 Stathmin STMN1 0007019; 0033556; 0030154 Microtubule depolymerization; Intracellular signat transduction; Cell differentiation
13, 18 DDAH1 DDAH1 0016403; 0045429; 0017014 Dimethylargininase activity; Positive regulation of NO biosynthetic process; Proteinnitrosylation
20, 237 γ-Enolase ENO2 0006096; 0001917 Glycolysis; Photoreceptor inner segment
21 GRP78 HSPA5 0030968; 0051087; 0043066 ER unfolded protein response; Chaperone binding; Negative regulation of apoptotic process
31 GAPDH GAPDH 0006096; 0051402; 0000226 Glycolysis; Neuron apoptotic process; Microtubule cytoskeleton organization
33 PPA1 PPA1 0004427 Inorganic diphosphatase activity
34 Calbindin CALB1 0005509; 0048167; 0010842 Calcium ion binding; Regulation of synaptic plasticity; Retina layer formation
37 NDPK B NME2 0004550; 0043066; 0010976 Nucleoside diphosphate kinase activity; Negative regulation of apoptotic process; Positiveregulation of neuron projection development
42 COX subunit 5A COX5A 0022904 Respiratory electron transport chain
91 γ-Synuclein SNCG 0014059; 0005815 Regulation of dopamine secretion; Microtubule organizing centre
a. Refers to that indicated in Figure 1C.
b. The protein pertaining to each spot and the name of its encoding gene are indicated.
c. Accession number(s) for each protein and most relevant associations found in the GO database in relation with the scope of this article.
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MS analysis allowed the identification of spot 31 (reduced by
1.37 fold in MPTP monkeys) as the GAPDH gene-encoded
glyceraldehyde 3-phosphate dehydrogenase. This is a NAD+-
dependent, relevant enzyme in the glycolytic pathway that
catalyzes the phosphorylation-coupled oxidation of D-
glyceraldehyde 3-phosphate to yield 1,3-bisphosphoglycerate.
However, GAPDH has roles additional to its classical function
as a glycolytic enzyme, also acting as a mediator of apoptosis
promoted by cytotoxic stressors in neurons [43] and bearing a
modulatory function of microtubule organization and dynamics
[44].
Spot 33 was found to represent inorganic pyrophosphatase
(showing a 1.67-fold in its normalized volume in the retina of
parkinsonian vs. control individuals), coded for by the PPA1
gene. This is a relevant enzyme in phosphate metabolism
carrying out the hydrolysis of pyrophosphate (PPi) to yield two
inorganic phosphate (Pi) molecules.
Spot 34 (whose intensity in the MPTP-treated retina was
1.65-fold lower than normal) was identified as calbindin D28k,
the product of CALB1. This is a ubiquitous, Ca2+-binding protein
with a relevant role in modulation of cytosolic Ca2+ levels and a
proposed neuroprotective role [45,46].
The second protein found overexpressed in parkinsonian
individuals (by 1.41-fold) was that represented by spot 37,
which was ascribed by MS analysis to nucleoside diphosphate
kinase B (NDPK B), encoded by the NME2 gene. This is a
cytoplasmic enzyme involved in the synthesis of nucleoside
triphosphates, catalyzing the conversion of XTP plus YDP into
XDP plus YTP (where X and Y are nucleosides other than
adenosine) through formation of a His-phosphorylated enzyme
intermediary form, although it may also act as a transcriptional
activator [47]. In the retina it provides a key role in recycling
GTP for phototransduction [48].
Spot 42 (which exhibited a volume reduction by 1.56-fold in
the MPTP-treated retina) was found to correspond to the
heme-containing, 5A subunit of cytochrome c oxidase (COX),
encoded by COX5A. This is a constituent protein of
mitochondrial complex IV, i.e. the terminal enzyme of the
electron respiratory chain whose well known function is the
transfer of electrons from cytochrome c to O2.
Finally, spot 91 was identified as γ-synuclein, encoded by the
SNCG gene (and whose levels turned out to be 1.56-fold
underexpressed in the treated monkeys). This protein plays a
role in neurofilament network integrity and is thought to
modulate axonal architecture during development and in the
adult stage [49,50].
Validation of Differentially-Expressed Proteins
Once analyzed and identified a series of proteins that
showed differential expression levels between parkinsonian
monkeys treated with the neurotoxin MPTP and controls, we
proceeded to validate the reliability of our proteomic approach
by Western blotting. With this purpose, three proteins were
selected for the sake of being involved in phototransduction (S-
arrestin and NDPK B) or being a good marker for cone
photoreceptors in primates (calbindin) [51], and their levels
detected in retinal extracts from parkinsonian and control
monkeys are shown in Figure 3A. The expression fold changes
shown in Figure 3B were calculated as the ratio between the
MPTP-treated and control normalized values. We confirmed
that levels of S-arrestin and calbindin were reduced, to 55.4%
and 53.4% with respect to controls, respectively, which was
coherent with decreases determined by DIGE. Also in keeping
with the latter, NDPK B levels were found increased in the PD
retina by Western blotting, by 7.84 fold as compared to
untreated subjects. These experiments were indicative that
DIGE combined with MS yielded results in the same direction
than immunoblotting regarding differential expression of
proteins in the retina of MPTP-treated monkeys.
Discussion
Proteomics approaches have been previously used to
address molecular alterations associated with a number of
neurodegenerative disorders, including PD [6,14,52–55],
Alzheimer disease (AD) [56–58] and Down syndrome [56], as
well as those accompanying aging [59], in the brains of both
human patients and animal models. Proteomic comparative
analyses have also been undertaken on the retinas of human
patients and animal models of Leber congenital amaurosis [60],
age-related macular degeneration (AMD) [61–63], glaucoma
[64] and diabetic retinopathy (DR) [65–68]. However, research
at the proteome level of molecular alterations associated with
PD in the retina of human or parkinsonian experimental
animals has not been conducted so far. We have undertaken in
this work a proteomic analysis of molecular alterations present
in the retina of monkeys treated with the proneurotoxin MPTP,
an animal model of parkinsonism where our group has
previously described the existence of significant retinal
impairments at the morphological and synaptic levels [21].
Proteins found in this work to undergo a decrease (most cases)
or increase in their abundance in this animal model can be
grouped into three main functional categories, as follows.
Enzymes Involved in Energy Metabolism
We have determined in the retina of parkinsonian monkeys a
lower abundance of enzymes involved in glycolysis, such as
GAPDH and α- and γ-enolases. A reduced content of GAPDH
has also been reported in the retina of streptozotocin-treated,
DR rats [65]. Regarding enolases, the α polypeptide is
expressed in most tissues, while the γ subunit is present
exclusively in neurons, where functional enolase dimers mainly
consist of γ/γ homodimers and α/γ heterodimers [69,70]. γ-
Enolase plays roles additional to its function as a glycolytic
enzyme, exhibiting neurotrophic and neuroprotective effects on
cultured neocortical, mesencephalic and spinal cord neurons
[41,71]. Alterations in γ-enolase levels have been reported in
the cerebral cortex of mice with a KO mutation in the Park2
gene, encoding parkin [55]. Here it is relevant to emphasize
that loss-of-function mutations in the human PARK2 gene are
associated with autosomal recessive PD with juvenile onset
[72]. Regarding the retina, α-enolase is found underexpressed
at the onset of human AMD [61], and in aged rats this enzyme
is irreversibly inactivated by the covalent addition of 4-
hydroxynonenal (4HNE) [73], a reactive aldehyde derived from
polyunsaturated fatty acid peroxidation that also accumulates
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in the brain of Park2 KO mice [14]. Both α- and γ-enolases
undergo nitrosative modification as well in the AD human brain
[74]. Therefore, oxidation or nitrosylation of these enzymes in
the CNS could bring about an impairment in glycolysis-coupled
energy production, with especially harming effects in retinal
neurons given their high energetic demand. Our observation of
a decrease in levels of GAPDH together with those of α- and γ-
enolases suggests the operation in the retina of a feed-back
negative regulatory mechanism of glycolysis in response to
blockade of mitochondrial complex I. Other glycolytic enzymes
downregulated in the pathological retina are aldolase C at the
onset of AMD [61] and triose phosphate isomerase in alloxan-
treated, DR model rats [67], while underexpressed Krebs cycle
enzymes include pyruvate dehydrogenase in the midbrain of
Park2 KO mice [14] and rotenone-treated rats [75]. In keeping
with our hypotesis, it has been previously proposed that
neurons respond to induced inhibition of mitochondrial
respiration and increasing of reactive oxygen species (ROS) by
Figure 3.  Western blotting validation of differentially expressed proteins in the retina of parkinsonian monkeys.  A.
Detection of S-arrestin (SAG; 48 kDa), calbindin (CB; 28 kDa) and nucleoside diphosphate kinase B (NDPK B; 17 kDa) in MPTP-
treated and untreated monkeys by Western blotting. β-Actin (42 kDa) levels are shown as loading controls. B. The amount of protein
present in each band was densitometrically measured and the value obtained for each detected protein was normalized to β-actin
levels. Protein expression fold changes are shown, obtained as the ratio between MPTP-treated and control values, and taking the
latter as 1.0. Bars represent the average ± SEM (n = 3).
doi: 10.1371/journal.pone.0074439.g003
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actively downregulating glycolysis (through the action of the
ubiquitin-proteasome pathway), giving priority to the
consumption of glucose to maintain an antioxidant status over
its use to fulfill their bioenergetic requirements [76].
We have also observed a reduction in the content of the 5A
subunit of COX and β subunit of ATP synthase in the retina of
parkinsonian monkeys, two enzymes that are well known
constituents of mitochondrial complexes IV and V, respectively.
A reduced activity or presence of these or other mitochondrial
respiratory chain components has been reported in the brains
of idiopathic PD, AD and Down syndrome cases [56,77–79],
which has been correlated with a reduced respiratory capacity
of mitochondria from Park2 KO mice [14]. In the same context,
the contents of both α and β subunits of ATP synthase F1
complex are decreased in the retinal pigment epithelium of
AMD patients [63], as it is the case for the d subunit of the F0
complex (H+ channel) in the neural retina of DR rats [67].
Taken together, these data underscore that MPTP-induced
mitochondrial complex I dysfunction can lead to alterations in
the levels of other components of the respiratory chain, in
analogy to what occurs in PD [6,75,80] and other
neurodegenerative diseases affecting the brain and/or the
retina. In a related fashion, an additional enzyme whose levels
we have found decreased in the parkinsonian monkey retina is
inorganic pyrophosphatase 1 (PPA1), which is responsible for
modulating Pi levels and is intimately linked to cell survival
[81,82]. Given that its activity is coupled to reactions in which
PPi is released, and that it provides a thermodynamic pull for
many biosynthetic reactions, its lower levels found in our
experimental system are consistent with a situation in which
the production of ATP is decreased due to the MPTP-provoked
mitochondrial dysfunction.
Neuroprotective Mechanisms
We have detected alterations in the expression of a series of
proteins directly or indirectly related to neuronal protection
against a variety of stresses, either endogenous or exogenous,
in the retina of MPTP-treated monkeys. First, we have found
underexpressed two members of the 70 kDa family of heat
shock proteins (HSP70), namely HSC70 and GRP78,
compared to control individuals. HSC70 is a molecular
chaperone that functions to maintain protein homeostasis in
cells under normal and stress conditions [37]. Its pattern of
distribution in the rat retina includes all retinal layers, except
photoreceptor outer segments [83], and its expression levels
have been found by proteomic analysis diminished in the
striatum and cortex of Park2 KO mice [55]. As well, a
significant mRNA underexpression of its encoding gene,
HSPA8, occurs with age in the primate retina [84]. It follows
that its ameliorated levels found in PD or aging could underlie
the neurodegeneration occurring in these conditions, as
proposed for both the brain [58] and the retina [84]. On the
other hand, the intravitreal injection of HSC70 is protective
against acute light-induced damage in rats, increasing the
number of surviving photoreceptors [85]. Relatedly, GRP78 is a
rough-ER chaperone working in the unfolded-protein response
to prevent ER stress-induced cell death in the brain [86,87] and
retinal [88] neurons, a phenomenon associated with a number
of neurodegenerative diseases [37] including retinal disorders
[59,89]. GRP78 is expressed in photoreceptors, including their
outer segments [90,91], and attenuated levels of this protein
have been documented in the brain of PD patients [86] and the
cortex of Park2 KO mice [55], this pointing out to the
dysfunction of a neuroprotective mechanism additional to
HSC70 in our MPTP-treated monkeys.
We have detected DDAH1 levels to be lower in the retina of
PD macaques in this work, while DDAH2 has been found
downregulated in the DR rat retina [67]. These are monomeric
hydrolases expressed in the brain and other organs able to
degrade ADMA and MMA, two methylated L-arginine
derivatives which act as endogenous inhibitors of NOS, thereby
contributing to regulated NO levels in numerous disease states
[40]. Hence, a relationship exists between NO and protein
misfolding in neurodegenerative disorders [92] such as PD,
where nitrosative stress very often accompanies oxidative
stress [6,12,93]. In this context, levels of proteins protective
against the latter are diminished in the brains of PD patients
and Park2 KO mice, together with a reduced antioxidant
capacity and ability to respond to ROS generation [14,52]. In a
related fashion, parkin is found S-nitrosylated in the brains of
parkinsonian animal models and patients, this resulting in
inhibition of its ubiquitin E3 ligase activity and neuroprotective
function [93–95]. As well, TH itself is known to undergo Tyr
nitration in MPTP-treated mice, also resulting in its inactivation
[96]. Therefore, the decreased DDAH1 levels in the retina of
our parkinsonian monkeys should result in lower NO levels,
and thus be oriented at counteracting MPTP-derived nitrosative
stress consequences, in the same line of thought as proposed
for dopaminergic neurons of baboons [97] and mice [98,99]
brains, and for DDAH2 downregulation in the DR rat retina [67].
As a difference with other proteins above, β-crystallin B2 was
found overexpressed in the retina of parkinsonian monkeys. α-,
β- and γ-crystallins, in addition to being the main structural
constituents of the lens, are present in the neural retina and
brain, and their additional role as oxidative stress-inducible
chaperones of the small HSP family is especially clear for α-
crystallins [38,100]. The localization of β-crystallin B2 in the
mouse retina includes the inner segments of photoreceptors,
some cells of the inner nuclear layer and ganglion cells [101].
Overexpression of β-crystallin B2 has also been reported in the
retinas of rats suffering DR [68,102], optic nerve physical
damage [103] or normal aging [73]. Other α-, β- and/or γ-
crystallins also become upregulated in the retina of several
genetic rodent models of retinitis pigmentosa [104,105] and DR
model rats [66–68,102], and under light-induced retinal
degeneration [105], as well as in the human AD brain [57]. All
these investigations have led to the view that crystallins could
act, not only as chaperones, but also as factors promoting the
regrowth of neuronal processes, thereby participating in axonal
regeneration upon tissue damage [14,37,103]. Even, their level
increases (especially of α-crystallins) have been correlated with
the rate of photoreceptor loss [105].
Stathmin, encoded by the STMN1 gene, belongs to a family
of microtubule-destabilizing proteins with an important role in
cytoskeleton reorganization taking place during neuronal
differentiation in development and after lesion in adulthood
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[39,106]. It is thus involved in modulating axon integrity in the
nervous system, in the context of retinal plasticity and in
regeneration processes. The levels of this protein appear
reduced in the brains of patients with AD [107] and Down
syndrome [108], as well as in the AMD retinal proteome [61].
Stathmin decrease in the PD monkey retina could either reflect
the failure of a system in charge of maintaining microtubule
stability and axonal integrity in the retina, such dysfunction
contributing to neuronal degeneration. On the other hand, since
stathmin is a microtubule-depolymerizing protein, its reduction
could be aimed at counteracting neuronal morphology
derangement, as it could also be the case for GAPDH [44].
Further research is needed to discern between these
hypotheses.
Calbindin is a multifunctional cytoplasmic protein crucial in
the modulation of cytosolic Ca2+ levels and intracellular
signalling. It has been found that dopaminergic neurons that
express calbindin in the substantia nigra are spared from
degeneration in PD patients and MPTP-treated monkeys and
mice [45], and levels of this protein are reduced in the brain of
old mice [59]. This indicates that dysregulation of Ca2+ levels
could be one of the mechanisms underlying brain and retinal
neurodegeneration associated with parkinsonism, and points
out a likely preventive role of calbindin in this context. In a
related fashion, the levels of another potentially-
neuroprotective Ca2+-binding protein, the neuron-specific
calretinin, are diminished in the cortex of Park2 KO mice [55]
and in the retina of AMD patients [61].
Last in this group of neuroprotective proteins, γ-synuclein
was also found underexpressed in the retina in our PD monkey
model. This is a cytoplasmic protein whose function in the
retina is poorly understood, and that is mainly contained in
some ganglion cells and in optic nerve fibres [109]. It has been
proposed to play a role as a retinal chaperone, working to
restore the correct folding of anomalous proteins and prevent
their aggregation [110]. In this context, γ-synuclein has shown
some neuroprotective effects on a photoreceptor cell line
expressing a retinitis pigmentosa-causative dominant allele of
the rhodopsin gene, P23H [111], encoding a misfolded,
cytotoxic variant of this protein.
Visual Signal Transduction
S-Arrestin, also known as rod arrestin, is one of the most
abundant proteins in the outer segments, where it participates
in the regeneration phase of the phototransduction cascade
with restoration of high cGMP levels [36]. It binds to
photoactivated, phosphorylated rhodopsin, thereby preventing
its interaction with transducin and ensuing activation of cGMP
phosphodiesterase 6B (PDE6B) [48]. Therefore, the attenuated
S-arrestin expression we have found in MPTP monkeys would
act in the sense of keeping PDE6B active and, consequently,
Na+ and Ca2+ cGMP-gated channels closed, with ensuing cell
hyperpolarization and cessation of Glu release in photoreceptor
axon terminals. Somewhat surprisingly, interaction of S-arrestin
with α-enolase has been recently reported to modulate the
activity of the latter, in the sense of reducing its catalytic rate
[112]. Conversely, and more in line with our results, mutations
in the SAG gene have been associated with Oguchi disease, a
variant of retinitis pigmentosa [113].
We have also found that NDPK B is overexpressed in the
retina of parkinsonian monkeys. This protein, among other
functions, provides the necessary intracellular GTP for
transducin and guanylate cyclase activities. Two hexameric
isoforms of this enzyme, A and B, are present in the retina [48],
of which the B isoform is known to form a complex with the Gβγ
heterodimer of various G proteins, including transducin.
Actually, NDPK B and transducin copurify from rod outer
segment membranes [114], and transducin is long known to
mediate interaction of NDPK (A and B) with (bleached) rod
outer segment membranes [115]. Furthermore, transducin Gβγ
is likely to be a substrate for His phosphorylation by NDPK B in
the retina [116]. Our results thus suggest that in parkinsonian
monkeys an increased activation of transducin could take place
independently of photoactivated rhodopsin in an NDPK B-
mediated fashion, this enhancing PDE6B activity and thereby
decreasing cGMP intracellular levels. The NDPK B increase
would thus act in the same direction as S-arrestin
underexpression, i.e. contributing to keep Na+ and Ca2+ cGMP-
gated channels closed. Very interestingly, the NDPK B-
encoding mRNA is overexpressed in the degenerating retina of
the rd/rd mouse, a retinitis pigmentosa model lacking PDE6B
[104].
The alteration in S-arrestin and NDPK B levels reflects, in
our belief, a protective response by photoreceptors to
mitochondrial damage. Since NDPK B appears to be a stress-
inducible protein, its rise together with α- and β-crystallin
upregulation may be a component of the stress response to
photoreceptor loss and altered retinal architecture [104]. In this
picture, Na+/Ca2+ channel closure would be aimed at preventing
a sustained elevation of intracellular Ca2+, which would trigger
apoptotic death of photoreceptors [117], as well as at avoiding
the energy expenditure required to maintain the dark current
[118]. In fact, such high energetic demand could not be fulfilled
by mitochondria in a situation of depressed metabolism plus
oxidative stress, where the additionally superimposed calbindin
downregulation would hamper the buffering of such Ca2+
increase [119].
Conclusions
This study is the first in providing direct evidence of
molecular alterations in the retina associated with PD, obtained
from a proteomics approach. Proteins found with altered levels
can be classified as related to: i) impairment of energy
metabolism (particularly concerning the glycolytic pathway and
mitochondrial ATP synthesis); ii) neuronal protection against
various stresses; and iii) visual signal transduction. Most of
these alterations act in the sense of potentiating
neuroprotective mechanisms aimed at counteracting MPTP
oxidative damage and/or promoting cell survival. The
downregulated levels found for proteins crucial for glycolysis
and mitochondrial electron transport chain reflect, in our view
and in consistency with previous proteomic studies on
parkinsonian human and animal-model brains, a feed-back
cellular response to mitochondrial complex I inactivation
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oriented to diminish the global rate of cellular energy
metabolism and/or the excess production of ROS ensuing
mitochondrial dysfunction. Other alterations occurred in the
sense of ameliorating nitrosative stress, increasing chaperone
activity, counteracting morphological degeneration or lowering
the phototransduction rate itself. Nevertheless, some
decreases of protein expression (such as the lower presence of
HSC70, GRP78, calbindin and γ-synuclein, and as discussed
above for stathmin) may simply reflect a failure or dysregulation
of protective neuronal systems. This would be a direct
consequence of the intracellularly generated oxidative stress
and subsequent intracellular damage, similar to that seen in the
aging process [84], in cells that have irreversibly entered the
apoptotic way and thereby contributing to its progression. This
is consistent with the finding that in the human PD substantia
nigra alterations in the mRNA levels of some genes do
accelerate cell death activity, whereas other retard or attempt
to compensate this process [120], as also concluded from other
proteomics studies tackling neurodegenerative diseases. It
follows that a complex set of mechanisms including
neuroprotective responses as well as neuronal death appears
to be involved in PD onset or progression, whose interplay
should require a good number of further studies to be clarified.
Loss of dopaminergic amacrines and their postsynaptic cells
in the peripheral retina of MPTP-treated monkeys has been
suggested to impair the scotopic visual pathway [21]. However,
recent studies on PD patients indicate that foveal vision is
impaired in humans, as evidenced by thinning of the inner
retina in the macular region detected by optical coherence
tomography (OCT) [15,17,121], which together with loss of
electrical activity recorded in the fovea reflects a deficit in the
photopic pathway [122–124]. Differences in the retinal
proteomes of monkeys treated with the parkinsonism inducer
MPTP compared to control animals point out to important
functional groupings (energy metabolism, protein folding vs.
degradation, stress response, neuronal survival vs. apoptosis,
signal transduction pathways, cytoskeletal dynamics and
others) and particular protein actors that have been implicated
as well in the pathogenesis of a number of CNS disorders in
humans and animal models, some of which also affect the
retina. It can thus be inferred that common intracellular agents
and molecular mechanisms, whose involvement in
neurodegenerative processes in the brain is increasingly
known, are implicated as well in retinal degenerations,
including PD-derived derangement of retinal neurons and
retina-specific diseases. Further studies are needed to more
exactly dilucidate the role of each of them in retinal
neurodegeneration in monkeys treated with MPTP, and in
terms of PD in general, and to unravel the levels at which they
are interrelated. This information could eventually be useful to
develop pharmacotherapies targeting fundamental biochemical
defects aimed at retarding disease progression and/or
alleviating neurodegeneration symptoms in the the retina and
brain.
Supporting Information
Figure S1.  MS/MS spectrum of a peptide identified by de
novo sequencing.  The fragmentation spectrum of a calbindin
precursor peptide (spot no. 34) is shown, which was identified
by de novo sequencing using the Sherenga algorithm. Its
amino acid sequence obtained from database search using the
Spectrum Mill software is indicated at the top of the image
(MSTag), and that interpreted by the Sherenga algorithm is
given below (upper and lower graphs, respectively). Graphs
show the relative intensity (%) of each peptide fragment plotted
as a function of its m/z value, indicated above its corresponding
peak.
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Table S1. Peptides identified by MALDI-TOF MS. 
Spot 
no.a 
Proteina Number of 
peptidesb 
Identified peptidesc 
1 α-Enolase 16/46 (R)AAVPSGASTGIYEALELR(D) 
   (K)FGANAILGVSLAVCK(A) 
   (R)HIADLAGNSEVILPVPAFNVINGGSHAGNK(L) 
   (K)LAMQEFMILPVGAANFR(E) 
   (K)LAmQEFMILPVGAANFR(E) 
   (K)LAmQEFmILPVGAANFR(E) 
   (R)IGAEVYHNLKNVIK(E) 
   (K)DATNVGDEGGFAPNILENK(E) 
   (K)VVIGMDVAASEFFR(S) 
   (K)VVIGMDVAASEFFR(S) 
   (R)YISPDQLADLYK(S) 
   (K)DYPVVSIEDPFDQDDWGAWQK(F) 
   (K)FTASAGIQVVGDDLTVTNPK(R) 
   (K)VNQIGSVTESLQACK(L) 
   (K)LAQANGWGVMVSHR(S) 
   (R)SGETEDTFIADLVVGLCTGQIK(T) 
5 -Crystallin B2 15/20 (K)AGSVLVQAGPWVGYEQANCK(G) 
   (K)GEQFVFEK(G) 
   (K)GEYPRWDSWTSSR(R) 
   (R)WDSWTSSR(R) 
   (K)IILYENPNFTGK(K) 
   (K)IILYENPNFTGKK(M) 
   (K)KMEIIDDDVPSFHAHGYQEK(V) 
   (K)MEIIDDDVPSFHAHGYQEK(V) 
   (R)VQSGTWVGYQYPGYR(G) 
   (R)GLQYLLEK(G) 
   (K)GDYKESSDFGAPHPQVQSVR(R) 
   (K)ESSDFGAPHPQVQSVR(R) 
   (R)IRDMQWHQR(G) 
   (R)IRDmQWHQR(G) 
   (R)DMQWHQR(G) 
18 N
G
,N
G
-Dimethylarginine 
dimethylamino-hydrolase 1 
(DDAH1) 
16/44 (R)ALPESLGQHALR(S) 
   (K)GEEVDVAR(A) 
   (R)QHQLYVGVLGSK(L) 
   (K)LQLNIVEMK(D) 
   (K)LQLNIVEMKDENATLDGGDVLFTGR(E) 
   (K)DENATLDGGDVLFTGR(E) 
   (R)EFFVGLSK(R) 
   (R)GAEILADTFK(D) 
   (K)DYAVSTVPVADGLHLK(S) 
   (K)SFCSMAGPNLIAIGSSESAQK(A) 
   (K)IMQQMSDHR(Y) 
   (K)LTVPDDIAANCIYLNIPNK(G) 
   (R)TPEEYPESAK(V) 
   (K)LKDHMLIPVSMSELEK(V) 
   (K)LKDHmLIPVSMSELEK(V) 
   (K)VDGLLTCCSVLINK(K) 
33 Inorganic pyrophosphatase 
(PPA1) 
18/40 (–)mYSWGVLAVRR(R) 
   (R)AAPFSLEYR(V) 
   (K)GQYISPFHDIPIYADK(D) 
   (K)GQYISPFHDIPIYADKDVFHMVVEVPR(W) 
   (K)DVFHMVVEVPR(W) 
   (R)YVANLFPYK(G) 
   (K)GYIWNYGAIPQTWEDPGHNDK(H) 
   (K)HTGCCGDNDPIDVCEIGSK(V) 
   (K)VLGILAMIDEGETDWK(V) 
   (K)VIAINVDDPDAANYNDINDVK(R) 
   (K)VIAINVDDPDAANYNDINDVKR(L) 
   (R)LKPGYLEATVDWFR(R) 
   (R)YKVPDGKPENEFAFNAEFK(D) 
   (K)VPDGKPENEFAFNAEFK(D) 
   (K)DKDFAIDIIK(S) 
   (K)GISCMNTTVSESPFK(C) 
   (K)GISCmNTTVSESPFK(C) 
   (R)AIVDALPPPCESACTVPTDVDK(W) 
237 -Enolase 21/44 (R)GNPTVEVDLYTAK(G) 
   (R)AAVPSGASTGIYEALELR(D) 
   (K)AVDHINSTIAPALISSGLSVVEQEK(L) 
   (K)LDNLMLELDGTENK(S) 
   (K)FGANAILGVSLAVCK(A) 
   (R)HIAQLAGNSDLILPVPAFNVINGGSHAGNK(L) 
   (K)LAMQEFMILPVGAESFR(D) 
   (K)LAmQEFMILPVGAESFR(D) 
   (R)LGAEVYHTLK(G) 
   (K)DATNVGDEGGFAPNILENSEALELVK(E) 
   (K)IVIGMDVAASEFHR(D) 
   (K)IVIGmDVAASEFHR(D) 
   (R)DGKYDLDFK(S) 
   (R)YITGDQLGTLYQDFVR(D) 
   (R)DYPVVSIEDPFDQDDWAAWSK(F) 
   (K)FTANVGIQIVGDDLTVTNPK(R) 
   (K)VNQIGSVTEAIQACK(L) 
   (K)LAQENGWGVMVSHR(S) 
   (K)LAQENGWGVmVSHR(S) 
   (R)SGETEDTFIADLVVGLCTGQIK(T) 
   (R)IEEELGDEAR(F) 
aThe spot number and the corresponding protein identified in each case are indicated.  
bThe number of peptides leading to each protein identification (selected on the basis of 
their m/z values matching those of peptide segments of the identified protein) is 
indicated together with the total number of peptides obtained by MALDI-TOF and used 
for database screening (separated by a slash).  
cThe sequence of the different peptides whose calculated m/z corresponds to that 
obtained by MALDI-TOF is shown. Residues in parentheses at both ends of each 
peptide were inferred from tryptic digestion, except ( ), unknown. Lowercase m stands 
for oxidized Met. 
Table S2. Peptides identified by LC-MS/MS. 
Spot 
no. 
Protein Identified peptides Score z SPI 
(%) 
MH+ mass 
(Da) 
1 α-Enolase (K)VNQIGSVTESLQACK(L) 24.97 2 96.4 1633.8 
  (R)AAVPSGASTGIYEALELR(D) 24.00 2 94.9 1804.9 
  (R)SGKYDLDFKSPDDPSR(Y) 23.97 3 96.2 1826.9 
  (K)VVIGmDVAASEFFR(S) 23.31 2 95.5 1540.8 
  (K)LAmQEFmILPVGAANFR(E) 23.09 3 95.8 1908.0 
  (K)DATNVGDEGGFAPNILENK(E) 22.26 2 97.1 1960.9 
  (R)YISPDQLADLYK(S) 19.78 2 96.6 1425.7 
  (R)GNPTVEVDLFTSK(G) 19.24 2 91.4 1406.7 
  (K)LmIEmDGTENK(S) 18.10 2 100.0 1280.6 
  (R)LGAEVYHTLK(G) 16.40 2 87.0 1130.6 
  (K)LAQANGWGVmVSHR(S) 14.96 3 74.2 1525.8 
  (K)KLNVTEQEKIDK(L) 14.60 3 82.1 1444.8 
2 ATP synthase, subunit 
β 
(R)TREGNDLYHEMIESGVINLK(D) 23.00 3 100.0 2318.1 
  (R)FTQAGSEVSALLGR(I) 22.50 2 100.0 1435.8 
  (K)VLDSGAPIKIPVGPETLGR(I) 22.32 3 96.5 1919.1 
  (K)VALVYGQMNEPPGAR(A) 21.92 2 97.5 1601.8 
  (K)TVLIMELINNVAK(A) 21.50 2 100.0 1457.8 
  (R)VALTGLTVAEYFR(D) 20.42 2 98.7 1439.8 
  (R)LVLEVAQHLGESTVR(T) 20.06 2 97.3 1650.9 
  (R)VALTGLTVAEYFRDQEGQDVLLFIDNIFR(F) 20.00 3 96.3 3342.7 
  (R)TIAMDGTEGLVR(G) 19.22 2 99.1 1262.6 
  (R)IPSAVGYQPTLATDMGTMQER(I) 18.62 3 87.8 2266.1 
  (R)EGNDLYHEMIESGVINLK(D) 18.21 3 96.3 2061.0 
  (R)IMDPNIVGSEHYDVAR(G) 17.62 3 95.1 1815.9 
  (K)AHGGYSVFAGVGER(T) 16.93 3 91.6 1406.7 
  (R)FLSQPFQVAEVFTGHMGK(L) 16.59 3 93.7 2023.0 
  (R)AIAELGIYPAVDPLDSTSR(I) 15.91 3 81.2 1988.0 
  (R)IVAVIGAVVDVQFDEGLPPILNALEVQGR(E) 15.02 3 84.7 3031.7 
  (R)IMNVIGEPIDER(G) 14.73 2 92.3 1385.7 
  (K)IPVGPETLGR(I) 14.07 2 87.3 1038.6 
  (K)VLDSGAPIK(I) 13.68 2 96.5 899.5 
  (R)IMNVIGEPIDERGPIK(T) 13.36 3 71.1 1781.0 
  (K)VVDLLAPYAK(G) 12.52 2 85.3 1088.6 
3 S-Arrestin (R)VQVYPPVGAASTPTK(L) 15.08 2 92.4 1514.8 
  (K)VYVTLTCAFR(Y) 14.92 2 92.8 1229.6 
  (K)LQESLLKK(L) 14.52 3 93.2 958.6 
  (R)DKSVTIYLGK(R) 13.56 2 87.8 1123.6 
  (K)KVYVTLTCAFR(Y) 12.71 3 79.1 1357.7 
  (K)SCGVDFEVK(A) 10.01 2 65.1 1040.5 
7 Heat shock 70 kDa 
protein 8 (HSC70) 
(K)STAGDTHLGGEDFDNR(M) 18.11 2 89.6 1691.7 
  (K)NQVAmNPTNTVFDAKR(L) 17.81 3 87.0 1805.9 
  (K)DAGTIAGLNVLR(I) 16.96 2 82.5 1199.7 
  (K)NSLESYAFNMK(A) 12.96 2 74.7 1303.6 
  (R)LSKEEIERmVnEAEK(Y) 8.60 3 71.2 1804.9 
12 Stathmin (R)ASGQAFELILSPR(S) 16.38 2 91.7 1388.8 
  (K)AIEENNNFSK(M) 15.20 2 83.7 1165.5 
13 NG,NG-
Dimethylarginine 
dimethylamino-
(K)DENATLDGGDVLFTGR(E) 23.55 2 97.0 1679.8 
hydrolase 1 (DDAH1) 
  (R)TPEEYPESAK(V) 21.15 2 95.2 1150.5 
  (K)VDGLLTCCSVLINK(K) 19.88 2 95.7 1591.8 
  (R)ALPESLGQHALR(S) 18.80 2 91.9 1291.7 
  (K)LQLNIVEmK(D) 18.44 2 93.1 1087.6 
  (R)GAEILADTFK(D) 18.07 2 93.4 1064.6 
  (R)QHQLYVGVLGSK(L) 16.41 3 80.4 1328.7 
  (K)DYAVSTVPVADGLHLK(S) 16.11 2 82.5 1684.9 
18 DDAH1 (K)DENATLDGGDVLFTGR(E) 21.92 2 98.9 1679.8 
  (K)VDGLLTCCSVLINK(K) 20.77 2 96.4 1591.8 
  (K)SFCSMAGPNLIAIGSSESAQK(A) 19.57 3 93.6 2155.0 
  (K)LTVPDDIAANCIYLNIPNK(G) 18.72 3 95.0 2144.1 
  (K)LQLNIVEMK(D) 16.90 2 95.6 1087.6 
  (R)ALPESLGQHALR(S) 16.83 2 93.3 1291.7 
  (R)GAEILADTFK(D) 16.81 2 95.8 1064.6 
  (R)GAEILADTFKDYAVSTVPVADGLHLK(S) 16.75 3 89.7 2730.4 
  (K)LKDHMLIPVSMSELEK(V) 15.29 3 88.2 1870.0 
  (K)DYAVSTVPVADGLHLK(S) 14.90 2 86.0 1684.9 
  (R)TPEEYPESAKVYEK(L) 14.52 3 75.0 1669.8 
  (R)EFFVGLSKR(T) 13.72 2 82.3 1082.6 
  (R)QHQLYVGVLGSK(L) 11.97 2 84.9 1328.7 
20 -Enolase (K)VNQIGSVTEAIQACK(L) 23.87 2 95.8 1617.8 
  IEEEIGDEAR 165a    
21 Glucose-regulated 78 
kDa protein (GRP78) 
(R)ITPSYVAFTPEGER(L) 19.32 2 94.6 1566.8 
  (K)VTHAVVTVPAYFNDAQR(Q) 17.25 3 85.2 1888.0 
  (K)SQIFSTASDNQPTVTIK(V) 16.34 3 78.9 1836.9 
  (R)IINEPTAAAIAYGLDKR(E) 15.40 3 93.3 1816.0 
31 Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
(K)LISWYDNEFGYSNR(V) 20.59 2 96.3 1763.8 
  (R)VPTANVSVVDLTCR(L) 16.87 2 91.0 1530.8 
  (K)VGVNGFGR(I) 15.84 2 87.9 805.4 
33 Inorganic 
pyrophosphatase 
(PPA1) 
(K)HTGCCGDNDPIDVCEIGSK(V) 22.94 3 95.0 2133.9 
  (K)mEIATKDPLNPIK(Q) 20.82 3 90.8 1469.8 
  (K)GISCmNTTVSESPFK(C) 20.14 2 96.7 1657.8 
  (K)GISCmNTTVSESPFKCDPDAAR(A) 17.90 3 87.9 2443.1 
  (R)AAPFSLEYR(V) 17.22 2 95.7 1053.5 
  (K)VIAINVDDPDAANYNDINDVKR(L) 16.25 3 91.5 2444.2 
  (R)YVANLFPYK(G) 14.55 2 89.0 1114.6 
  (K)DPLNPIKQDVK(K) 14.25 2 81.5 1266.7 
34 Calbindin (R)LLPVQENFLIK(F) 17.43 2 93.7 1313.8 
  IAEYTDIFIQ 154a    
37 Nucleoside 
diphosphate kinase B 
(NDPK B) 
(R)GDFCIQVGR(N) 17.74 2 89.9 1051.5 
  (R)TFIAIKPDGVQR(G) 15.03 2 83.3 1344.8 
  (R)LMLGETNPADSKPGTIR(G) 11.72 3 83.4 1799.9 
42 Cytochrome c oxidase 
(COX), subunit 5A 
(K)GINTLVTYDLVPEPK(I) 21.95 2 94.6 1658.9 
  (R)LNDFASTVR(I) 14.45 2 82.6 1022.5 
91 -Synuclein (K)TKEQANAVSEAVVSSVNTVAAK(T) 20.44 3 96.6 2203.2 
  (K)TVEEAENIAVTSGVVR(K) 20.22 2 95.4 1673.9 
  (K)EQANAVSEAVVSSVNTVAAK(T) 18.48 2 95.5 1974.0 
  (K)TVEEAENIAVTSGVVRK(E) 17.08 3 93.5 1802.0 
  (K)TKENVVHSVTSVAEK(T) 10.50 3 75.1 1627.9 
  (K)EGVmYVGTK(T) 10.14 2 87.4 983.5 
115 S-Arrestin (K)ESYQDANLVFEEFAR(H) 22.19 3 95.4 1817.8 
  (R)KVQHAPLEmGPQPR(A) 21.82 3 96.0 1587.8 
  (K)VYVTLTCAFR(Y) 20.74 2 95.7 1229.6 
  (R)VQVYPPVGAASTPTK(L) 19.55 2 93.7 1514.8 
  (R)LmHPQPEDPAK(E) 18.04 2 85.3 1262.6 
  (K)TLTLLPLLANNR(E) 17.14 2 75.4 1338.8 
  (K)VQHAPLEMGPQPR(A) 16.15 3 83.3 1459.7 
  (K)IKHEDTNLASSTIIK(E) 14.25 3 86.4 1669.9 
  (K)SCGVDFEVK(A) 13.05 2 81.9 1040.5 
  (R)DKSVTIYLGK(R) 12.70 2 85.0 1123.6 
  (K)SVTIYLGK(R) 12.39 2 90.9 880.5 
237 -Enolase (K)DATNVGDEGGFAPNILENSEALELVK(E) 19.31 3 97.4 2702.3 
  (K)FGANAILGVSLAVCK(A) 18.64 2 82.4 1519.8 
  (K)FTANVGIQIVGDDLTVTNPK(R) 18.24 2 87.9 2102.1 
  (K)SKFGANAILGVSLAVCK(A) 17.24 3 84.6 1735.0 
  (K)LDNLMLELDGTENK(S) 16.95 3 92.1 1604.8 
  (R)LGAEVYHTLK(G) 16.69 3 96.0 1130.6 
  (R)AAVPSGASTGIYEALELR(D) 16.04 3 79.1 1804.9 
  (K)AVDHINSTIAPALISSGLSVVEQEK(L) 15.13 3 77.3 2578.4 
  (R)GNPTVEVDLYTAK(G) 15.12 2 86.4 1406.7 
  (K)LAMQEFMILPVGAESFR(D) 14.53 2 84.2 1939.0 
  (K)ACNCLLLK(V) 13.23 2 83.5 991.5 
  (R)IEEELGDEAR(F) 12.36 2 71.9 1160.5 
  (K)LAQENGWGVMVSHR(S) 11.56 2 71.3 1583.8 
The sequence of the different peptides identified by LC-MS/MS are given for each spot 
together with the corresponding protein. Residues in parentheses at both ends of each 
peptide were inferred from tryptic digestion, and lowercase m stands for oxidized Met. For 
each peptide the MS/MS score is given together with its charge (z) and its scored peak 
intensity (SPI). The last column shows the monoisotopic mass (MH+) of each peptide. 
aPeptides identified by de novo sequencing using the Sherenga algorithm. 
